LUCD
Lucid Diagnostics Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.43
+5.03%Year over year
Reported trailing growth
- Revenue
- +24.9%
- EBITDA
- +5.5%
- EBIT
- -5.7%
- EPS
- +55.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +137.7%
- EBITDA
- +34.6%
- EPS
- +58.9%
Three-year CAGR
- Revenue
- +132.0%
- EBITDA
- -28.8%
- EBIT
- -7.8%
- Net income
- -27.4%
- EPS
- +34.3%
- Free cash flow
- -3.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026